Carl Zeiss Meditec AG
XETRA:AFX

Watchlist Manager
Carl Zeiss Meditec AG Logo
Carl Zeiss Meditec AG
XETRA:AFX
Watchlist
Price: 27.84 EUR 0.36% Market Closed
Market Cap: €2.5B

ROE

5.8%
Current
Declining
by 4.6%
vs 3-y average of 10.4%

Return on Equity (ROE) measures how effectively a company generates profit from shareholders` equity. It shows how much net income is earned for each dollar invested by shareholders.

ROE
5.8%
=
Net Income
€120.6m
/
Avg Total Equity
€2.1B

Return on Equity (ROE) measures how effectively a company generates profit from shareholders` equity. It shows how much net income is earned for each dollar invested by shareholders.

ROE
5.8%
=
Net Income
€120.6m
/
Avg Total Equity
€2.1B

Peer Comparison

Country Company Market Cap ROE
DE
Carl Zeiss Meditec AG
XETRA:AFX
2.4B EUR
Loading...
US
Abbott Laboratories
NYSE:ABT
168.1B USD
Loading...
US
Intuitive Surgical Inc
NASDAQ:ISRG
166.6B USD
Loading...
US
Stryker Corp
NYSE:SYK
131.3B USD
Loading...
IE
Medtronic PLC
NYSE:MDT
110.6B USD
Loading...
US
Boston Scientific Corp
NYSE:BSX
95.3B USD
Loading...
DE
Siemens Healthineers AG
XETRA:SHL
43.9B EUR
Loading...
US
Edwards Lifesciences Corp
NYSE:EW
47B USD
Loading...
US
IDEXX Laboratories Inc
NASDAQ:IDXX
47B USD
Loading...
US
Becton Dickinson and Co
NYSE:BDX
45.1B USD
Loading...
US
GE Healthcare Technologies Inc
NASDAQ:GEHC
34B USD
Loading...

Market Distribution

In line with most companies in Germany
Percentile
46th
Based on 2 908 companies
46th percentile
5.8%
Low
-2 076.4% — 1.1%
Typical Range
1.1% — 12.3%
High
12.3% — 46 778.5%
Distribution Statistics
Germany
Min -2 076.4%
30th Percentile 1.1%
Median 6.8%
70th Percentile 12.3%
Max 46 778.5%

Carl Zeiss Meditec AG
Glance View

Carl Zeiss Meditec AG stands as a beacon in the realm of medical technology, carving a niche through its innovative solutions in ophthalmology and microsurgery. Rooted in the prestigious legacy of the Zeiss Group, this company seamlessly fuses cutting-edge technology with practical medical applications. Its headquarters in Jena, Germany, serve as the crucible for pioneering research and development endeavors, channeling expertise into products that enhance both diagnostic and surgical capabilities. The heart of its operations revolves around creating technological marvels such as optical coherence tomography (OCT) instruments and surgical microscopes, which bring precision and enhanced clarity to the medical field. Through a well-executed blend of R&D and strategic acquisitions, Carl Zeiss Meditec consistently remains at the forefront of medical innovation, ensuring it meets the ever-evolving needs of the healthcare sector. Financially, the company thrives by selling its sophisticated medical devices directly to healthcare professionals, hospitals, and clinics worldwide. Rather than merely creating instruments, Carl Zeiss Meditec's business model is deeply entwined with providing comprehensive workflow solutions and service support, ensuring that medical practitioners extract maximum utility from their investments. By offering not just products but also extensive after-sales service and maintenance, the company builds sustained relationships with its clients, fostering a cycle of trust and repeat business. In addition, its engagement in training and support services enhances user competencies, ensuring the seamless integration of its technology into everyday medical practice and underscoring its commitment to elevating healthcare standards globally. Through this multifaceted approach, Carl Zeiss Meditec solidifies its position as an indispensable ally in the medical community, both as a supplier of state-of-the-art equipment and as a provider of essential healthcare solutions.

AFX Intrinsic Value
LOCKED
Unlock
What is Return on Equity?
Return on Equity (ROE) measures how effectively a company generates profit from shareholders` equity. It shows how much net income is earned for each dollar invested by shareholders.
How is ROE calculated?

ROE is calculated by dividing the Net Income by the Avg Total Equity.

ROE
5.8%
=
Net Income
€120.6m
/
Avg Total Equity
€2.1B
What is Carl Zeiss Meditec AG's current ROE?

The current ROE for Carl Zeiss Meditec AG is 5.8%, which is below its 3-year median of 10.4%.

How has ROE changed over time?

Over the last 3 years, Carl Zeiss Meditec AG’s ROE has decreased from 16.7% to 5.8%. During this period, it reached a low of 5.8% on Jan 1, 2026 and a high of 16.7% on Dec 31, 2022.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett